Richard Howard Drew, PharmD

• Professor in Medicine

https://medicine.duke.edu/faculty/richard-howard-drew-pharmd

One pooled analysis and one meta-analysis showed that associations were not statistically significant 160 cholesterol in eggs pdf buy abana 60 pills mastercard,161 when only cohort studies were included cholesterol ratio with hdl generic 60pills abana mastercard, suggesting that recall and selection bias might account for some of the findings cholesterol ratio units purchase 60 pills abana otc. Thus cholesterol score chart uk buy 60 pills abana visa, they have the potential (similar tamoxifen) block oestrogen action; this might reduce risk. However, for postmenopausal women who have low levels of endogenous oestrogens, 50,157 phytoestrogens could conceivably increase oestrogen action. Isoflavones are a class of phytoestrogen contained in soybeans and derived foods such as tofu and miso, and in some legumes. Because these foods are consumed in Asian countries, which have lower rates of breast cancer, the hypothesis that they reduce risk has attracted scientific and popular attention. Some of the case?control studies and none of the cohort studies showed reductions in risk with increased dietary intake of soy products during adulthood. A few studies have used biomarkers of phytoestrogen intake by measuring compounds in urine or blood serum, but findings from these are also inconsistent. Thus, there is little evidence support a role for phytoestrogensinfluencing breast cancer risk, at least in adulthood. It is possible that it might be necessary consume phytoestrogens during adolescence or at very high doses produce a long-term reduction of breast cancer risk. A number of studies report that high consumption of various vitamins (including A, C and D either from diet or from supplements) is associated with a decreased risk of 164 breast cancer, but the studies are few and the findings are inconsistent. A recent meta-analysis concluded that there is no clear support for an overall relationship 165 between folate intake or blood folate levels and breast cancer risk. On the other hand, an adequate folate intake might reduce the increased risk of breast cancer that has been associated with moderate or high alcohol consumption, by counterbalancing the negative effect of alcohol on 165 folate absorption (see also Section 7. It has been suggested that dietary fibre, obtained from vegetables, fruits and wholegrain cereal products, might reduce risk of breast cancer by altering the absorption of oestrogens by the intestines. Studies investigating the association between fibre intake and decreased breast cancer risk have produced conflicting findings. Two other prospective studies did not 167, 168 show any effect of fibre intake on breast cancer risk. Caffeine is a substance produced by the leaves, beans or nuts of different plants, and is contained in coffee, tea, chocolate and cola drinks. Most studies of breast cancer have shown no 50 associations with intake of caffeine-containing beverages. A recent meta-analysis examined studies of the association between consumption of either green tea or black tea and breast 169 cancer risk. Such analyses overcome limitations of the single-food or nutrient approach, including failing account for interaction between nutrients, intercorrelations between nutrients and the inability detect small effects of single nutrients. Consequently, dietary patterns may be more strongly associated with disease risk than specific food or nutrients. Few cohort studies have investigated associations between dietary intake patterns and breast 170 cancer risk. Others have 172 reported increased risk associated with a pattern characterised by high consumption of alcohol and yet others have found no evidence of association between dietary pattern and breast cancer 173 risk. Breast cancer risk factors: a review of the evidence 39 An intervention trial for postmenopausal women was designed promote change in dietary patterns, with the goal of reducing total fat intake 20% of energy and increasing consumption 174 of vegetables and fruit. An increase in consumption of vegetables and fruits and decrease in consumption of meat is apparent in Australia (see Figure 6). Figure 6 Consumption of selected foodstuffs in Australia, 1938?1938 1998?1999 7. A collaborative reanalysis was conducted on individual data from 53 epidemiological studies, including 176 58,515 women with breast cancer and 95,067 women without breast cancer. Although there was little elevation in risk of breast cancer for low levels of alcohol consumption (ie less than one standard drink per day), compared with women who reported drinking no alcohol, the relative risk was 1. Similar findings were obtained from a pooled analysis of six prospective cohort studies of 177 322,647 women followed for up 11 years, including 4335 women with breast cancer. Adjustment for a range of breast cancer risk factors did not modify the 178 findings of either study, and findings differed minimally by study design characteristics. Increased levels of circulating 179 oestrogens and androgens have been suggested as the most likely mechanism. Alcohol might also act negatively on folate absorption and metabolism and evidence from epidemiological studies discussed in Section 7. In 2004?2005, 54% of Australian women aged 18 or older reported consuming alcoholic beverages in the previous week. In the past 10 years, the proportion of adult women aged under 65 drinking more than two standard drinks of alcohol per day increased from around 6% 13% 122 (see Figure 7). The average consumption of alcohol in Australia is somewhat higher than the 176 6 g/day (about half a drink) reported by the pooled analysis. Assuming that the relationship is causal, approximately 2?5% of breast cancers in Australia could be attributed alcohol consumption. Figure 7 Percentage of Australian women reporting drinking more than two standard drinks of alcohol per s day Breast cancer risk factors: a review of the evidence 41 7. Epidemiological studies have reported positive, inverse and null associations between cigarette smoking and breast cancer. At least three critical reviews that examined the published literature on smoking and breast cancer concluded that cigarette smoking might be associated with a small increase in breast 180-182 cancer risk, particularly for smoking of long duration. A meta-analysis of 44 studies published between 1984 and 2001 reported a combined relative risk of 1. The combined relative risk increased with increasing intensity of exposure (cigarettes smoked per day) and increasing duration of smoking (years). Evidence of positive associations between breast cancer and cigarette smoking was also published in a report where non-smoking women who were exposed passive, second-hand 181 smoke were excluded from the comparison group. In addition, studies suggest that the risk of 180 breast cancer associated with smoking might be increased for premenopausal women or women who started smoking in their mid-teens or earlier, or before their first full-term 180,182-184 pregnancy. Similarly, women who inherited specific variants in genes involved in the metabolism of carcinogens found in tobacco might experience higher risks associated with 181,182,185 smoking cigarettes. The hypothesis that cigarette smoking is associated with breast cancer risk was not confirmed by Collaborative Group on Hormonal Factors in Breast Cancer, which reported in 2002 the findings from a pooled analysis of data from 53 epidemiological studies that compared ever smokers with never smokers, using 22,255 women with breast cancer and 40,832 controls. Women who reported drinking alcohol were excluded from the analysis examine the association with cigarette smoking alone. These are transported by the blood stream the breast, as shown by studies of fluids expressed from the breast, of adipose tissue surrounding the epithelial cell ducts and of p53 mutations found in breast tissue of smokers compared with non-smokers. Tobacco smoke also has possible anti oestrogenic properties, as suggested by smokers having earlier menopause, lower breast density measures, higher rates of osteoporosis and lower risks of other hormone-dependent 182 gynaecological conditions compared with non-smokers. If the carcinogenic effects of smoking are counterbalanced by the anti-oestrogenic effects, the result might be no net effect or a very small effect on the overall risk of breast cancer. On the other hand, it is possible in an overall analysis that strong effects might be obscured for important subgroups of women based on the timing of their exposure tobacco smoke in relation breast development, or their genetic makeup or exposure other factors. Despite years of educational campaigns describing the health hazards of cigarette smoking, one in four Australian adults smoke. Overall, 20% of adult women smoke; but in the 18?34 age 42 Breast cancer risk factors: a review of the evidence 122 bracket 26% of women are smokers. From 1995 2004, the proportion of women aged 18 122 34 who smoked decreased, but increased for women aged 35?54. With respect body size, women who are taller than 175 cm have a breast cancer risk 30?40% higher than women shorter than 160 cm. Regular physical activity appears decrease postmenopausal breast cancer risk, mainly through weight control. There is limited evidence that physical activity is associated with decreased premenopausal breast cancer risk. The role of diet in the development of breast cancer is probably less important than for some other cancers (eg head and neck). The evidence regarding an association between high consumption of fat or red meat and increased risk of breast cancer is still limited and the effect, if any, is likely be small. Women with the highest consumption of fat or red meat would have a breast cancer risk 10?20% higher than that for women with the lowest consumption. It is possible that high consumption of vegetables or fruit is associated with a small decrease in breast cancer risk, but the evidence is limited. Studies have investigated several other foods, beverages, nutrients and vitamins, but the data are either of too low quality, too inconsistent, or based on too few studies allow conclusions be reached. In contrast, drinking alcoholic beverages, whether beer, wine or spirits, is associated with breast cancer risk. For each additional standard drink per day, breast cancer risk increases by around 7%.

Coding guidelines Code the largest diameter of any involved regional lymph nodes for head and neck (cervical lymph nodes) cholesterol medication options cheap abana 60 pills without a prescription. Pathological measurement takes precedence over a clinical measurement for the same node cholesterol definition simple purchase generic abana on line. Only use these codes when the pathologist has used this terminology cholesterol test canada purchase abana in united states online indicate the lymph node size xanthelasma/ cholesterol eyelid deposits purchase 60pills abana mastercard. Note 2: If the same largest involved node (or same level) is examined both clinically and pathologically, record the size of the node from the pathology report, even if it is smaller. Note 3: If the largest involved node is not examined pathologically, use the clinical node size. A schema discriminator is necessary distinguish between these primary sites so that the appropriate chapter/schema is used. Coding Instructions and Codes Note: A schema discriminator is used discriminate for primary site C111: Posterior wall of nasopharynx. Chapter 10 is now for p16+ tumors, while Chapter 11 is for p16 negative tumors or where the p16 is not assessed or unknown. A schema discriminator is necessary determine the p16 status so that the appropriate chapter/schema is used. Definition In addition the tumor size (diameter, not depth), the presence of certain specific high-risk features is of prognostic significance for skin cancers of the head and neck. Undifferentiated (grade 4) Note 3: Code the presence or absence of high risk histologic features as documented in the pathology report. The cardia is defined as the opening or junction between the esophagus and the stomach, and it is between 0. This 2-cm boundary measurement is based on the Siewert classification of gastroesophageal cancers, which defines an area 2 cm above and 2 cm below the cardia or esophagogastric junction. Both of these areas are coded primary site C160, so a discriminator is needed get the correct chapter. To determine whether a cancer of the cardia should be coded according the esophagus schema or the stomach chapter, it is necessary identify the midpoint or epicenter of the tumor. A schema discriminator is necessary distinguish between these histologies so that the appropriate stage group table is used. Coding Instructions and Codes Note: A schema discriminator is used discriminate for histology 8020/3: Undifferentiated carcinoma determine which Stage Group table use. Coding Instructions and Codes Note 1: this data item is used for pathological staging for squamous cell carcinoma of the esophagus and esophagogastric junction. Note 2: Location is defined by the position of the epicenter of the tumor in the esophagus. Example: If the lesion was from 15-21 cm, this is a 6-cm lesion with epicenter at 18 cm. Note 3: Clinician or pathologist statement of epicenter being the upper, middle, or lower takes priority over any individual results or measurements. If no statement of epicenter is provided indicating upper, middle, or lower is provided, the following measurements may be used. If you have an overlapping tumor (C158), do not recode the topography based on the epicenter. The lab value may be recorded in a lab report, history and physical, or clinical statement in the pathology report. This may also be referred as the Radial Resection Margin or surgical clearance. For segments of the colon completely encased by peritoneum, the mesenteric resection margin is the only relevant circumferential margin. For rectal cancers, the circumferential resection margin is the most important predictor of local-regional recurrence. Note 2: Tumor involvement of the circumferential resection margin or radial resection margin appears be a strong prognostic factor for local or systemic recurrences and survival after surgery. If the margin is described as less than 1 mm with no more specific measurement, Code 0. When mutated, oncogenes have the potential cause normal cells become cancerous. Definition Describes cancer cells that have a greater than normal number of genetic markers called microsatellites. Microsatellite instability is found most often in colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer. Knowing whether cancer is microsatellite instability high may help plan the best treatment. Definition Perineural invasion is infiltration of nerves in the area of the lesion by tumor cells or spread of tumor along the nerve pathway. If perineural invasion is not mentioned in the pathology report, do not assume that there is no perineural invasion. Note 2: Code the presence or absence of perineural invasion by the primary tumor as documented in the pathology report. Absence of perineural invasion can only be taken from a surgical resection pathology report. Code Description 0 Perineural invasion not identified/not present 1 Perineural invasion identified/present 8 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 8 may result in an edit error. Definition Tumor deposits are separate nodules or deposits of malignant cells in perirectal or pericolic fat without evidence of residual lymph node tissue. If present, tumor deposits may be found within the primary lymphatic drainage area of the tumor. They are different from direct extension from the primary tumor and may be the result of lymphovascular invasion with extravascular extension, a totally replaced lymph node, or discontinuous spread. Nodules of tumor outside the primary lymphatic drainage area of the tumor are distant metastasis. Coding Instructions and Codes Note 1: Physician statement of Tumor Deposits can be used code this data item when no other information is available. Note 2: Tumor deposits are defined as one or more satellite peritumoral nodules in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule. Note 4: Code X9 if surgical resection of the primary site is performed, the pathology report is available, and tumor deposits are not mentioned. Code Description 00 No tumor deposits 01 01-99 Tumor deposits 99 (Exact number of Tumor Deposits) X1 100 or more Tumor Deposits X2 Tumor Deposits identified, number unknown X8 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code X8 may result in an edit error. Alpha fetoprotein levels are usually undetectable in the blood of healthy adult men or women (who are not pregnant). An elevated level of alpha-fetoprotein suggests the presence of either a primary liver cancer or germ cell tumor. Note 3: A lab value expressed in micrograms per liter (ug/L) is equivalent the same value expressed in ng/ml. Code Description 0 Negative/normal; within normal limits 1 Positive/elevated 2 Borderline; undetermined if positive or negative 7 Test ordered, results not in chart 8 Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code 8 will result in an edit error. If the liver is damaged, there will be too much bilirubin in the blood, and this can produce jaundice. Elevated bilirubin levels can indicate liver or blood disorders or blockage of bile ducts. Do not code individual conjugate, direct, unconjugated, indirect, or delta values or bilirubin in urine. Creatinine can be measured in blood serum or urine, but these data items apply blood levels only. An elevated level indicates the blood is too thin and does not clot properly, increasing the risk of bleeding. Note 2: Record the lab value of the highest Bilirubin Total test results documented in the medical record prior treatment. Note 3: Assay of Bilirubin Pretreatment Total Lab Value includes conjugated (direct) and unconjugated (indirect) bilirubin and total bilirubin values. Note 4: Record the nearest tenth of mg/dL or umol/L the highest total bilirubin value prior treatment. Bilirubin is commonly measured in units of Milligrams/deciliter (mg/dL) in the United States and Micromoles/liter (umol/L) in Canada and Europe.

Buy abana. These 7 foods are the best for lower Cholesterol.

While systemic imaging is not recommended in routine breast cancer follow-up total cholesterol definition wikipedia generic abana 60pills line, breast-speci? After breast conservation surgery ideal cholesterol ratio ldl hdl abana 60 pills on line, we recommend a mammogram at 4 cholesterol levels young adults cheap abana express 6 months after completion of radiation and then annually unless speci? While in the absence of symptoms routine endometrial imaging or endometrial biopsies are not recommended cholesterol weight ratio discount 60pills abana, new onset bleeding should prompt a complete workup (10). Extended gene panels using next generation testing now identify medium/intermediate penetrance genes as well. Myelodysplastic syndrome and leukemia are a known rare sequela of chemo therapy and radiation. Alkylating agents (cyclophosphamide) and topoisomerase targeting drugs (anthracyclines) are the most frequently implicated and are used in many adjuvant breast cancer regimens (13). A review of over 20,000 patients with early-stage breast cancer treated between 1998 and 2007 found a marrow neoplasm cumulative incidence rate of 0. While the breast cancer stage, race, and tumor characteristics were not signifcantly diferent in those who developed marrow neoplasm versus those without, patients with marrow neoplasms were signifcantly older (13). While there is no recommenda tion for routine testing with a complete blood count, incidentally discovered cyto penias or symptoms such as infections/fatigue/bruising/bleeding should prompt workup (4). Preexisting cardiac disease and risk stratifcation should be taken into consideration prior initiating therapies. They recommend patients receive education of possible cardiac symptoms, smoking cessation, diet, exercise, and monitoring of periodic lipid levels per the U. Anthracyclines Chronic/late-onset anthracycline-induced cardiac toxicity presents within a few months decades afer the last dose of chemotherapy and progresses from an asymptomatic cardiomyopathy overt heart failure. The cause of the cardiac tox icity is still unclear, but the primary mechanism is likely related oxidative stress and damage myocytes (14,15). The strongest risk factor for the development of cardiac toxicity is the life time cumulative dose of anthracycline. The risk of cardiac toxicity increases sharply afer 400 450 mg/m2 for doxorubicin although with substantial indi vidual variation (17). In the adjuvant setting, concurrent and posttreat ment heart function assessments are not usually necessary in the low-risk patient. Dexrazoxane is a chelating agent that has a cardioprotective efect when treating with high-dose anthracyclines (18). However, there is a theoretical risk of decreasing the efcacy of anthracycline treatment with the chelator. Terefore, dex razoxane is not recommended for breast cancer patients who are undergoing poten tially curative/adjuvant treatment with anthracycline-based regimens. For patients with metastatic disease receiving higher cumulative doses of doxorubicin, dexra zoxane should be added afer initial doses exceed 300 mg/m2. Routine assessment of ejection fraction should occur afer 250 300 mg/m2 and again between 400 and 450 mg/m2. Once a dose of 500 mg/m2 is reached, monitoring of ejection fraction should be completed every 50 mg/m2. A decline in ejection fraction of less than the lower limit of normal or the clinical development of heart failure are indications for stopping the chemotherapy. Epirubicin is an anthracycline also used in the treat ment of breast cancer with the maximum cumulative dose limit at 900 mg/m2 (18). Follow-up clinical studies that excluded patients with preexisting decreased ejection fraction showed signifcantly less cardiac toxicity. A meta-analysis of nearly 12,000 patients receiving trastuzumab showed that the overall incidence of cardiac toxicity resulting in congestive heart failure was 2. Risk factors for trastuzumab-induced cardiac toxicity include anthracycline exposure (concurrent or previous), increased age, hypertension, and obesity (23,24). The nonanthracycline regimen of docetaxel/carboplatin/tras tuzumab/pertuzumab had the lowest incidence of cardiac dysfunction with the highest pathologic complete response rate (25). When used in the neoadjuvant setting, the package insert recommends cardiac monitoring every 6 weeks. Radiation Older radiotherapy techniques for breast cancer involved signifcant doses of radi ation the heart. The spectrum of radiation-related cardiac disease includes myocardial damage and coronary artery disease when mediastinal radiation is used (31). This improvement could be related improved techniques or possibly decreased targeting of the internal mammary lymph nodes. It is unclear if one potentiates the efects of the other or if each has an independent mechanism (23). Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastu zumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Cognitive Impairment and Fatigue Seventy-fve percent of breast cancer patients report decline of cognitive function during their treatment and 35% report continuing impairment afer treatment ends (34?36). The presence of treatable and contributing factors of cognitive impairment such as depression, insomnia, substance abuse, medication efects, and causes of fatigue should be evaluated (3,4). However, ofen no distinct cause can be identifed and the patient is assumed have cognitive impairment related treatment. Tese subtle yet signifcant efects on cognitive functioning can have a large impact on quality of life (37,38). Breast cancer patients appear be particularly susceptible cognitive defcits for numerous reasons including efects of cancer itself, emotional stress of the diagnosis, and the sequelae of chemotherapy and hormone therapy. Multiple stud ies have confrmed objective evidence of cognitive decline afer chemotherapy (37?39). Analyses using a battery of neuropsychological tests have shown defcits in various cognitive domains including visuospatial ability, executive function, information processing speed, and verbal and visual memory (40,41). Studies with brain imaging in breast cancer patients who have received chemotherapy show structural changes refective of treatment efects (42,43). In addition cytotoxic agents, breast cancer patients with hormone-receptor positive breast cancer receive adjuvant hormonal therapy. As health care providers for breast cancer survivors, understanding the pos sibility of cognitive dysfunction and its efect on quality of life and function in society is essential. Fatigue is very common in cancer patients treated with radiation and chemo therapy, and some patients experience longer lasting symptoms causing disrup tions in quality of life and increased distress. Estrogen has been shown have anti depressive efects, and treatment for breast cancer can lead an estrogen-deprived state (48). We recommend the use of the distress thermometer, Patient Health Question naire-9 or -12, or the General Anxiety Disorder 7 item scale; validated screening tools for distress, depression, and anxiety; these should be implemented regularly. Identifcation of substance abuse is also important as it can exacerbate any mental illness (49?51). In collaboration with their primary care physicians, breast cancer survivors should undergo routine assessments for signs and symptoms of insomnia, depres sion, anxiety, and distress. To ensure appropriate and timely management, there should be a low threshold refer these patients mental health professionals for evalua tion and management. Counseling, mindful meditation, hope therapy, and making meaningful interventions have helped many breast cancer survivors (52). Tese high rates of depression may be due a multitude of factors including body image issues, physical efects of treatment, loss of sexual function, ongoing fatigue, and perpetual concern about recurrence. Despite the high rates of depression and anxiety among breast cancer patients, dedicated studies on management of these patients are lacking. Pharma cotherapy and psychotherapy are the mainstay of treatment for mild moderate depression and anxiety. A review of the side efects may be helpful in treating concomitant problems the patient may face (insomnia, appetite issues, pains, hot fashes). Short-term use of benzodiazepines in cases of anxiety may be necessary but long-term use should be limited. For those taking tamoxifen, the antidepressive medications duloxetine, sertraline, fuvoxamine, paroxetine, fuoxetine, and bupropion may inhibit metabolism of tamoxifen its active metabolites via the cytochrome P450 2D6 enzymes, leading a decrease in therapeutic efect of tamoxifen. In this situa tion, alternative antidepressants should be considered if possible (55). Sleep disorders are prominent in cancer patients and may contribute cogni tive impairment, fatigue, and depression. Treating contributing factors such as pain, hot fashes, sleep apnea, and activating medications are important steps in address ing sleep disorders. Review of sleep hygiene, exercise times, cafeine consumption, and meditation techniques may help regulate sleep.

Among them cholesterol levels by age and gender discount abana master card, 6 (23%) patients received Risk reducing procedures (Prophylactic mastectomy or oophorectomy) and most of them(19 patients(73%)) received cancer specific screening cholesterol levels uk average purchase abana without prescription. Conclusion We demonstrate the use of multigene panel testing for hereditary breast cancer and will suggest the process of the genetic counseling including indication and results analysis with multigene panel testing cholesterol medication elderly buy abana 60pills fast delivery. We conducted 4 focus groups with purposive sampling of women who responded cholesterol medication long term effects discount abana online amex the survey. Although stigma was not associated with genetic testing uptake in our survey data, it emerged as a prominent factor in decision-making among focus group participants due its potential impact on marriageability and family. Among non-Modern Orthodox women, rabbinic consultation was an important factor in genetic testing decision-making. The majority of patients were of European (66%) or African (31%) American ancestry; 26% had a family history and 13% had died of disease with an average time death of 2. University Hospital of South Manchester, Manchester, United Kingdom; University of 3 4 Manchester, Manchester, United Kingdom; Karolinska Institute, Stockholm, Sweden; University of Cambridge, Cambridge, 5 United Kingdom and Queen Mary University of London, London, United Kingdom. Women at increased familial risk of breast cancer (n=135) aged 33-46 agreed take tamoxifen for five years for breast cancer prevention. Controls (n=204) were of the same age and risk, undergoing annual mammography in the same clinic. We report response data for each technique related median change in dense volume or dense area after one year and 4-5 years of tamoxifen treatment. The median and interquartile ranges for change in density from baseline year 1 were 10. Virtually all of the reduction in density seen at one year was sustained for as long as treatment continued. In summary, we demonstrate that change in density as a result of tamoxifen treatment may be evaluated by automated techniques which may be more applicable than visual techniques in the clinic. Institute of Genetics and Molecular 2 Medicine, University of Edinburgh, Edinburgh, United Kingdom and Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom. The aim was validate this test in cohorts of both pre and post-menopausal women treated with two weeks of a variety of endocrine treatments (tamoxifen, fulvestrant or an aromatase inhibitor) prior surgery. The 5 and 10 year actuarial recurrence rates were 7%/22% and 46%/73% for the low and high risk groups, respectively. The 5 and 10 year actuarial recurrence rates were 12%/29% and 27%/77% for the low and high risk groups, respectively. As a result, the cost effective role of clinical risk assessment with histopathology of breast carcinomas tends be minimized. Patients had five years of follow-up with tumor registry and were treated with endocrine therapy alone. At 5 years, 433 patients (98%) were alive, 8 were dead, 1 from breast cancer due distant recurrence. Body: Background Polymorphisms of genes involved in estrogen production have been linked breast cancer risk, prognosis and treatment response. Serum and whole blood was taken at baseline and the day before surgery and stored at -80?C until assayed. The association of genetic polymorphisms with any event was assessed by the Cox proportional hazards models adjusted for confounders. Further genomic profiling in larger trials aimed enhance tailored treatment efficacy in endocrine-responsive postmenopausal breast cancer are warranted. These results were supported by Western blots from the cell lines examined under various growth conditions. This combination might be an interesting treatment option for tamoxifen-resistant patients. Hokkaido University Hospital, Sapporo, Hokkaido, Japan; Hokkaido University Hospital, Sapporo, Hokkaido, 3 Japan and Research Division of Companion Diagnostics, Hokkaido University Hospital, Sapporo, Hokkaido, Japan. Correlations between these biological markers and clinicopathological factors and prognosis were analyzed separately in pre and postmenopausal women. A long follow up retrospective study 1 1 1 1 1 1 1 1 Miguel Gil-Gil, Idoia Morilla, Anna Petit, Teresa Soler, Xavier Perez-Martin, Anna Guma, Maria Jesus Pla, Raul Ortega, 1 1 1,2 1 1 1 1 Amparo Garcia-Tejedor, Catalina Falo, Robert Montal, Luis Perez-Casanova, Carolina Loayza and Sonia Pernas. Surgical specimen: ypT1 36%, ypT2 54%, ypT3 6%, ypT4 4%; ypN0 28%, ypN1 22%, ypN2 13. Irradiation volumes (breast or chest wall +/ regional lymph nodes) were defined per standard of care. Cumulative incidence rates and hazard ratio were obtained using both Cox and Fine-Gray models, taking into account metastatic relapse and death as competitive events. Similar results were obtained when taking locoregional relapses synchronous with distant metastatic disease into account (interaction test: p=0. Moreover, the finding that cM0(i+) status is a predictive marker for the efficacy of locoregional lymph node irradiation promises a new opportunity better tailor adjuvant radiation therapy in early stage breast cancer patients. Lund University, Lund, Sweden; Lund University Cancer Center, Medicon Village, Lund, Sweden; 3 4 5 Skane University Hospital, Lund, Sweden; Blekinge County Hospital, Karlskrona, Sweden; Skane University Hospital, Malmo, 6 7 8 Sweden; Skane University Hospital, Malmo, Sweden; Skane University Hospital, Lund, Sweden; Lund University, Lund, 9 Sweden and Skane University Hospital, Lund, Sweden. For 405 breast tumors in the training cohort, a comprehensive histopathological biomarker evaluation was performed by three pathology readings estimate inter-pathologist variability on the original diagnostic slides as well as on repeat immunostains for this study, and the consensus biomarker status for all five conventional biomarkers was determined. All patients underwent upfront breast surgery; hence there are no confounding effects of neoadjuvant treatment on biomarker levels. Results: There were 56 patients in the paclitaxel arm (A), 115 in the Paclitaxel+Neratinib arm (B), 22 patients on the Paclitaxel + Trastuzumab arm (C) and 72 on the Paclitaxel + Veliparib + Carboplatin arm (D). A custom nCounter (Nanostring Technologies) gene expression panel was designed and both the training and validation cohorts were analyzed with the custom panel. Clinicopathologic variables were abstracted from pathology reports, and were available for a subset of these cases. Fudan University Shanghai Cancer Center, Shanghai, China; Cancer Institute, 3 Fudan University Shanghai Cancer Center, Shanghai, China and Shanghai Medical College, Fudan University, Shanghai, China. The slope of the calibration curve was close 1, which indicated excellent calibration of the nomogram. As a secondary objective, we explored if a model based on the clinicopathologic variables can accurately predict recurrence score. As a second step, we used these results and clinical expertise guide a predictive model. We present an option identify patients whose risk category can be confidently determined from the standard clinicopathologic variables alone, thereby reducing medical cost. Admittedly, this model has not undergone validation nonetheless, the data suggest the potential for a novel; low-cost; high reach diagnostic tool. Body: Background: Even after successful treatment of primary breast tumors, there is a continued risk of recurrence. In this study, we profiled protein expression in blood plasma from patients with known clinical outcome (recurrence vs no recurrence) identify prognostic markers of breast cancer recurrence. We analyzed blood plasma samples taken at the time of diagnosis from consented patients who subsequently relapsed (33 cases) as well as those with no disease recurrence (31 controls). Even though there was a lack of significantly differentiated proteins between the cases and controls of this group, many significant gene sets were identified. Overall survival was measured from start of first-line (L1) treatment; patients without evidence of death were censored at the last observed visit. Presence of bone metastasis was a significant predictor of higher risk for disease progression. University of North Carolina; University of North Carolina Lineberger Comphrehensive Cancer Center; 3 4 University of North Carolina and University of North Carlina. Delays in initiation of first treatment were modeled in two ways: i) time initiation >30 days from diagnosis, and ii) time initiation above the 75th percentile. Extended duration and delay in completion were defined as being > 75th percentile in days between initiation and end of treatment (duration) or days from diagnosis end of treatment (completion) compared others in the same pathway. Interestingly, adjustment for tumor characteristics did not impact effect estimates. Significant racial disparities remained in delay across all phases of care after adjustment for clinical, demographic and access factors. Overall, black women were at higher risk of delays in treatment initiation, extended duration and time completion than white women receiving similar treatment, and these disparities appear be compounded over the care continuum. University of North Carolina; University of North Carolina Lineberger Comphrehensive Cancer Center; University 4 5 of North Carolina, School of Public Health; National Cancer Institute and University of North Carolina, School of Public Health. Propensity score models included age, race, diagnosis year, co-morbidity, and tumor features.

References

• Hayward NJ, Elliott PJ, Sawyer SD, et al. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996;139: 188-202.
• Shapiro MJ, Albelda SM, Mayock RL, McLean GK. Severe hemoptysis associated with pulmonary aspergilloma. Percutaneous intracavitary treatment. Chest 1988;94:1225-31.
• Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology. 1985;35:1173-1176.
• Soylemezoglu F, Soffer D, Onol B, et al. Lipomatous medulloblastoma in adults. A distinct clinicopathological entity. Am J Surg Pathol 1996; 20(4):413-418.
• Saklad M. Grading of patients for surgical procedures. Anesthesia 1941;2:281-284.
• Califf RM, Mark DB, Harrell FE Jr, et al: Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J Am Coll Cardiol 1988;11:20-26.
• Levine LA, Rybak J: Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study, J Sex Med 8:2112n2117, 2011.
• Irwin M, Daniels M, Weiner H. Immune and neuro-endocrine changes after bereavement. Psychiatric Clin North Am 1987;10:449-65.